| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | PTA1; DNAM1; DNAM-1; TLiSA1 |
| Entrez GeneID | 10666 |
| clone | 4D8E1B4 |
| WB Predicted band size | 38.6kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD226 (AA: extra 19-254) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD226抗体的3篇文献及其摘要的简要列举：
1. **标题**：*CD226 promotes anti-tumor immunity by regulating T cell activity*
**作者**：Wang, Y., Xu, Z., & Zheng, P.
**摘要**：该研究揭示CD226在T细胞介导的抗肿瘤免疫中的关键作用，其通过增强T细胞与肿瘤细胞的结合及激活下游信号通路，与PD-1等免疫检查点存在协同调控机制。
2. **标题**：*Targeting CD226 for modulating autoimmune inflammation*
**作者**：Liu, X., & Chen, L.
**摘要**：文章探讨CD226在自身免疫性疾病(如多发性硬化症)中的表达异常，发现阻断CD226抗体可减少炎性细胞浸润并缓解疾病症状，提示其作为潜在治疗靶点。
3. **标题**：*CD226 blockade enhances the efficacy of CAR-T cell therapy*
**作者**：Zhang, H., et al.
**摘要**：研究证明，抑制CD226信号可减少CAR-T细胞耗竭并提高其持久性，在小鼠模型中显著增强对实体瘤的治疗效果，为联合疗法提供理论支持。
4. **标题**：*CD226 and TIGIT interplay in NK cell-mediated immune surveillance*
**作者**：Shibuya, A., & Tahara-Hanaoka, S.
**摘要**：该文献解析CD226与其抑制性受体TIGIT在NK细胞功能中的动态平衡，指出CD226抗体可能通过打破这种平衡增强抗病毒及抗肿瘤免疫应答。
(注：上述文献为示例，实际引用需根据具体研究内容检索权威数据库。)
CD226. also known as DNAX accessory molecule-1 (DNAM-1), is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. It is expressed on various immune cells, including T cells, natural killer (NK) cells, platelets, and monocytes. CD226 plays a critical role in regulating immune responses by interacting with its ligands, CD112 (nectin-2) and CD155 (PVR), which are often overexpressed on tumor cells or infected cells. This interaction promotes immune cell adhesion, activation, and cytotoxicity, contributing to antitumor and antiviral immunity. Dysregulation of CD226 signaling is implicated in autoimmune diseases, cancer immune evasion, and infectious pathologies.
CD226 antibodies are tools or therapeutic agents designed to modulate CD226-mediated pathways. In research, anti-CD226 antibodies are used to study receptor-ligand interactions, immune synapse formation, and downstream signaling mechanisms. Therapeutically, agonist antibodies may enhance CD226 activity to boost immune cell targeting of tumors, while blocking antibodies could suppress excessive immune activation in autoimmune disorders. Recent studies highlight CD226 as a potential immune checkpoint target, with its expression and function often counterbalanced by inhibitory receptors like TIGIT. Preclinical models suggest that combining CD226-targeting antibodies with other immunotherapies (e.g., anti-PD-1) may improve outcomes. However, clinical translation requires further investigation into safety, efficacy, and the complex interplay between CD226 and coexisting immune regulatory pathways.
×
